Immunity Dynamics and Reinfection in SARS-CoV-2

The SARS-CoV-2 pandemic has spurred a global effort to characterise how immune responses evolve following infection and vaccination, and how these dynamics influence the risk of reinfection. Early waves of infection elicit both humoral and cellular immunity, with neutralising antibodies targeting spike-protein epitopes and memory T cells providing longer-term protection against severe disease. However, the emergence of antigenically distinct variants, especially Omicron and its subvariants, has revealed marked immune escape, leading to increased breakthrough infections despite high seroprevalence. Studies show that antibody titres peak within weeks of exposure or booster vaccination then decline steadily—a process known as immune waning—whereas T cell responses are generally more durable. Natural infection grants robust short-term protection against homologous strains but affords diminished cross-variant defence, while vaccine-induced immunity can be tailored by booster doses to restore neutralisation breadth. Hybrid immunity, arising from the combination of past infection and vaccination, emerges as the most durable shield against diverse variants, maintaining higher antibody levels and sustained memory responses. Despite these advances, reinfections continue to occur, particularly as immunity wanes and new variants arise, underscoring the need to refine booster strategies, monitor immune correlates and adapt vaccines to emerging lineages.

Research from Nature Portfolio

Large-scale analyses in Qatar have mapped the duration of mRNA vaccine effectiveness against Omicron BA.1 and BA.2, demonstrating that protection against symptomatic infection wanes to minimal levels within months after both the primary series and booster doses, whereas protection against hospitalisation remains above 90%. A parallel study using community PCR data found that previous infection or primary vaccination alone offers limited defence against Omicron subvariants, but that booster vaccination significantly augments neutralising responses, albeit with rapid decline over time. These findings underscore the challenge of sustaining protection against highly immune-evasive variants and highlight the importance of optimising booster timing and vaccine composition to prolong both mucosal and systemic immunity.

Immunity Dynamics and Reinfection in SARS-CoV-2 publication trend

The graph below shows the total number of articles in immunity dynamics and reinfection in sars-cov-2 across all publications each year (not limited to Nature Index journals).

Technical terms

Hybrid immunity: Immune protection derived from both prior infection and vaccination, offering broader and more durable responses.

Neutralising antibody: An antibody that directly blocks a virus from infecting host cells by binding viral surface proteins.

Immune waning: The gradual reduction in the magnitude of immune protection following infection or vaccination.

Reinfection: A new episode of infection by the same pathogen occurring after recovery from an initial infection.

Seroprevalence: The proportion of individuals in a population who have detectable specific antibodies against an infectious agent.

References

1. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nature Communications (2022).
2. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections. Nature Communications (2022).
3. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. The Lancet (2023).
4. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. The Lancet Infectious Diseases (2023).